OXM 001
Alternative Names: OXM-001; Oxyntomodulin analog - Nordic BioscienceLatest Information Update: 28 Oct 2023
At a glance
- Originator Nordic Bioscience
- Class Gastrointestinal hormones; Obesity therapies; Peptides
- Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Obesity in Denmark (SC)
- 12 Jun 2020 Updated pharmacodynamics data from preclinical trial in Obesity presented at the 80th Annual Scientific Sessions of the American Diabetes Association (ADA-2020)
- 16 Sep 2019 Pharmacodynamics data from a preclinical trial in Obesity presented at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD-2019)